The Impact of Triptorelin on Hormone Levels in Human and Its Metabolite Confirmation Using Liquid Chromatography-Ion Trap/Time-of-Flight Mass Spectrometry (LC/MS-IT-TOF) and Liquid Chromatography-Orbitrap (LC-Orbitrap) for Doping Control Analysis.
Saardpun. Navaporn N; Asawesna. Cholsittapan C; Kaewklam. Seksun S; Sangkhum. Premsant P; Kongchareonsombat. Wisoot W; Kusamran. Thanit T; Pinthong. Darawan D
Key Findings
- Triptorelin causes an initial rise then a strong suppression of LH and testosterone, outperforming leuprorelin in prostate cancer patients
- LH and testosterone levels dropped significantly after a single dose, measured at several time points up to three months
- A unique metabolite (triptorelin 5‑10) appears in urine/serum and can be detected with advanced LC‑MS methods for doping control
Practical Outcomes
- For the biohacker community, the main takeaway is that triptorelin is a very effective testosterone‑suppressing agent, but it’s a prescription cancer drug with serious risks and not suitable for casual use. The detection method also reminds that using such agents can be flagged in anti‑doping tests.
Summary
The study shows that the drug triptorelin, used for prostate cancer, strongly lowers LH and testosterone levels, more so than a similar drug, leuprorelin, and that a specific breakdown product shows up in urine and can be used to catch doping. While it confirms how powerful the hormone blocker is, the drug is prescription‑only and meant for serious medical conditions, so it isn’t a practical supplement for most self‑experimenters.
Abstract
Triptorelin, a synthetic gonadotrophin-releasing hormone (GnRH), is mainly used in the clinical treatment of prostate cancer. The mechanism initially stimulates luteinizing hormone (LH) and testosterone secretion followed by suppression, resulting in a reduction in cancer progression. However, GnRHs are prohibited in doping control because of the indirect surge of LH and testosterone. Therefore, GnRH analog detection and confirmation are enforced by World Anti-Doping Agency (WADA) requirements. The effects of triptorelin on LH and endogenous steroid levels in urine and serum of five prostate cancer patients taking triptorelin for the first time were investigated and compared with leuprorelin. The samples were collected at 0.0 h, 3.0 h, 6.0 h, 1 month, and 3 months later after drug administration. The effect of triptorelin on LH levels was measured using a sandwich enzyme-linked immunoassay (ELISA). Testosterone and endogenous steroid levels were monitored using gas chromatography coupled with mass spectrometry (GC/MS). Triptorelin showed an advantage over leuprorelin on LH and testosterone suppression, which is preferable to use for prostate cancer treatment. In this study, triptorelin (5-10), a unique in vivo metabolite, was found in urine and serum and verified with synthetic triptorelin (5-10). The metabolite was analyzed using liquid chromatography combined with Orbitrap (LC-Orbitrap) and liquid chromatography coupled with ion trap/time-of-flight mass spectrometry (LC/MS-IT-TOF). When triptorelin levels are undetectable, the presence of triptorelin (5-10) in human urine can be used as evidence that triptorelin is being misused in doping control.
Study Information
pubmed
2025
2025-01-05T00:00:00.000Z
10.1002/dta.3849
1
45